Literature DB >> 3348201

Prognostic factors in chronic myelodysplastic syndromes: a multivariate analysis in 107 cases.

S García1, M A Sanz, V Amigo, P Colomina, M D Carrera, J I Lorenzo, G F Sanz.   

Abstract

A retrospective multivariate analysis of 37 clinical, biochemical, and hematological data was performed in 107 cases of primary myelodysplastic syndromes (MDS) in order to recognize their prognostic significance. The most important individual variables, isolated in a previous univariate analysis, were placed in a multiple regression modeling procedure to identify major significant prognostic factors. Multivariate analysis tends to identify prognostic variables containing significant independent predictive information. Characteristics were examined on both continuous and binary bases. The FAB classification was the first parameter entered in regression equations on both models, followed by platelet count, hemoglobin level, and circulating erythroblasts in the binary model, and by hemoglobin level, systemic symptoms, platelet count, age, and dyserythropoiesis in the continuous model. Our analysis confirms FAB classification as the main prognostic factor in MDS, supports the previously noted predictive value of platelet count, hemoglobin level, and age, and recognises the importance of circulating erythroblasts, systemic symptoms, and dyserythropoiesis as prognostic characteristics in MDS.

Entities:  

Mesh:

Year:  1988        PMID: 3348201     DOI: 10.1002/ajh.2830270303

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  6 in total

Review 1.  Impact of growth factors in the regulation of apoptosis in low-risk myelodysplastic syndromes.

Authors:  R Tehranchi
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

2.  Prognostic relevance of histological findings on bone marrow biopsy in myelodysplastic syndromes.

Authors:  G Lambertenghi-Deliliers; C Annaloro; A Oriani; D Soligo; E Pozzoli; E E Polli
Journal:  Ann Hematol       Date:  1993-02       Impact factor: 3.673

3.  Correlations between cytogenetics and morphology in myelodysplastic syndromes.

Authors:  L Vila; C Charrin; E Archimbaud; D Treille-Ritouet; J Fraisse; P Felman; D Fiere; D Germain
Journal:  Blut       Date:  1990-04

4.  The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase-III intergroup study.

Authors:  K B Miller; K Kim; F S Morrison; J N Winter; J M Bennett; R S Neiman; D R Head; P A Cassileth; M J O'Connell; K Kyungmann
Journal:  Ann Hematol       Date:  1992-10       Impact factor: 3.673

Review 5.  Models of Prognostication in Chronic Myelomonocytic Leukemia.

Authors:  Francesco Onida
Journal:  Curr Hematol Malig Rep       Date:  2017-12       Impact factor: 3.952

Review 6.  FAB classification of myelodysplastic syndromes: merits and controversies.

Authors:  G E Verhoef; S Pittaluga; C De Wolf-Peeters; M A Boogaerts
Journal:  Ann Hematol       Date:  1995-07       Impact factor: 3.673

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.